Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock

Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock: A Multicenter Prospective Randomized Trial (CARBON)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Sepsis is a dysregulated host response to infection that leads to life-threatening organ dysfunction and represents a major healthcare problem. Septic shock is the most severe form, characterized by increased capillary permeability and vasodilation, resulting in hypotension and tissue hypoxia. Early identification and treatment of tissue hypoperfusion are pivotal components of initial resuscitation to limit progression to multiple organ dysfunction and death. The 2021 Surviving Sepsis Guidelines recommend guiding initial resuscitation by targeting decreases in serum lactate levels in patients with elevated lactate. However, although elevated lactate levels may reflect tissue hypoxia, serum lactate is not a direct marker of tissue perfusion. Hyperlactatemia may be attributable to mechanisms other than tissue hypoperfusion, such as accelerated aerobic glycolysis driven by excessive β-adrenergic stimulation or impaired clearance (e.g., in liver failure). The venous-to-arterial carbon dioxide partial pressure difference (CO₂ gap), which is inversely related to cardiac output, has been shown to reflect the adequacy of venous blood flow to remove CO₂ from tissues. The CO₂ gap is closely linked to microcirculatory blood flow during the early resuscitation phase of septic shock and may effectively identify persistent tissue hypoperfusion in shock states. A persistently high CO₂ gap during early resuscitation has been associated with significantly higher 28-day mortality and increased Sequential Organ Failure Assessment (SOFA) scores. Moreover, the CO₂ gap has been shown to respond to changes in cardiac output during inotrope infusion in patients with low blood flow, suggesting that its assessment could be useful for therapeutic adjustments. Therefore, there are compelling arguments to evaluate the usefulness of the CO₂ gap in guiding early resuscitation in patients with septic shock. The investigators postulated that CO₂ gap-guided early resuscitation may be more effective in improving outcomes than lactate-guided resuscitation.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients aged 18 years or older AND - Acutely admitted to a study ICU AND - Primary diagnosis of septic shock according to the Sepsis-3 criteria and defined as: - A suspected or documented site of infection or positive blood culture AND - Acute increase of at least 2 points in the Sequential Organ Failure Assessment (SOFA) score consequent to the infection AND - Having a serum lactate level \>2 mmol/l AND - Requirement of vasopressors (any dose of norepinephrine) to maintain mean arterial pressure (MAP) ≥65 mmHg despite adequate fluid resuscitation (at least 1L of IV fluid in the last 24 hours prior to screening) Who Should NOT Join This Trial: - Septic shock for more than 12 hours at the time of screening - Primary cause of hypotension not due to sepsis (e.g., acute bleeding) - Decision not to resuscitate (or to limit full care) or not to intubate taken before obtaining consent - Death is deemed to be imminent or inevitable or patients with an underlying disease process with a life expectancy of less than 3 months - Anticipated surgery during the first 24 hours after randomization - Patient or their relatives' refusal to participate - Patients participating in another RCT with interventions possibly compromising the primary outcome - Prior enrollment in the CARBON trial - Known to be pregnant. - Legal protection (i.e., incompetence to provide consent and no guardian or incarceration) - No affiliation with the French health care system Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients aged 18 years or older AND * Acutely admitted to a study ICU AND * Primary diagnosis of septic shock according to the Sepsis-3 criteria and defined as: * A suspected or documented site of infection or positive blood culture AND * Acute increase of at least 2 points in the Sequential Organ Failure Assessment (SOFA) score consequent to the infection AND * Having a serum lactate level \>2 mmol/l AND * Requirement of vasopressors (any dose of norepinephrine) to maintain mean arterial pressure (MAP) ≥65 mmHg despite adequate fluid resuscitation (at least 1L of IV fluid in the last 24 hours prior to screening) Exclusion Criteria: * Septic shock for more than 12 hours at the time of screening * Primary cause of hypotension not due to sepsis (e.g., acute bleeding) * Decision not to resuscitate (or to limit full care) or not to intubate taken before obtaining consent * Death is deemed to be imminent or inevitable or patients with an underlying disease process with a life expectancy of less than 3 months * Anticipated surgery during the first 24 hours after randomization * Patient or their relatives' refusal to participate * Patients participating in another RCT with interventions possibly compromising the primary outcome * Prior enrollment in the CARBON trial * Known to be pregnant. * Legal protection (i.e., incompetence to provide consent and no guardian or incarceration) * No affiliation with the French health care system

Treatments Being Tested

PROCEDURE

CO2gap-guided resuscitation strategy

For patients assigned to the interventional arm, adherence to the algorithm will complement clinical practices in the following areas: * Blood sampling for venous blood gas analysis. Blood samples will be taken from an existing central venous catheter; central venous access is common clinical practice in critically ill patients. * The use of dobutamine and blood transfusions in patients showing signs of oxygen deficiency (both will be carried out in accordance with the intended use and conditions of current practice).

Locations (20)

CHu Angers
Angers, France
CH Aurillac
Aurillac, France
CH de la Côte Basque
Bayonne, France
CHU Bordeaux Hôpital Haut Lévèque
Bordeaux, France
CHU Bordeaux Pellegrin Hospital
Bordeaux, France
CHU Clermont-Ferrand Estaing
Clermont-Ferrand, France
CHU Clermont-Ferrand Gabriel Montpied
Clermont-Ferrand, France
CHU Grenoble
Grenoble, France
CH Le puy en Velay
Le Puy-en-Velay, France
HCL - Lyon Sud
Lyon, France
HCL Hôpital Edouard Herriot
Lyon, France
CH Moulins-Yzeure
Moulins, France
CHU Nîmes
Nîmes, France
APHP Beaujon
Paris, France
APHP Bicêtre
Paris, France
APHP La pitié Salpêtrière - Anesthésie et soin intensif
Paris, France
APHP Lariboisière
Paris, France
CHU la pitié slapêtrière - Anesthésie Réanimation
Paris, France
CHU Rennes
Rennes, France
CHRU Strasbourg - Service d'anesthésie-Réanimation médicale
Strasbourg, France